Chul Kim, MD
Dr. Chul Kim is an Associate Professor at Georgetown University with a focus on thoracic oncology. His goal as a thoracic medical oncologist is to introduce innovative cancer therapies into clinical practice, and he is devoted to formulating clinical trials aimed at promoting personalized cancer treatments.
Dr. Kim's academic journey began at the Sungkyunkwan University School of Medicine in Seoul, South Korea, where he graduated Summa Cum Laude. He furthered his studies at the Harvard School of Public Health, obtaining a Master’s degree in Public Health. His medical training continued at the University of Minnesota where he trained in internal medicine. Later, he became a clinical fellow in hematology and oncology at the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
In 2018, Dr. Kim was honored with the Norman Rales Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). In 2021, he received the John F. Potter, MD, Award from Georgetown Lombardi Comprehensive Cancer Center.
Dr. Kim has authored more than 60 articles in reputable peer-reviewed journals, including Lancet Oncology, JAMA Oncology, Journal of Thoracic Oncology, Journal for ImmunoTherapy of Cancer, and Clinical Cancer Research. Additionally, he has served as a reviewer for various journals such as Journal of Clinical Oncology, Clinical Lung Cancer, Lancet HIV, Lancet Haematology, and JCO Precision Oncology.
He is an active member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer.
Driven by his commitment to patient care, Dr. Kim aims to provide the best possible treatment options for his patients. In his free time, he enjoys hiking, exploring diverse cuisines, and traveling with his wife and son.
Financial relationships
-
Attribution:SelfType of financial relationship:Contracted ResearchIneligible company:AstraZeneca, Novartis, Regeneron, Janssen, Genentech, Lyell, Daiichi Sankyo, Gilead, Macrogenics, Boehringer Ingelheim, Black Diamond TherapeuticsDate added:09/11/2024Date updated:09/11/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Arcus, AstraZeneca, Daiichi Sankyo, Eisai, Regeneron, Sanofi, Takeda, J&J, Pinetree, Boehringer Ingelheim, GencurixDate added:09/11/2024Date updated:09/11/2024